Has Keytruda’s patent expiry been extended in the EU?
Yes. Keytruda (pembrolizumab) has had its EU exclusivity/patent position extended through later-patent filings and patent-life extensions, including events tied to the European patent system and court activity. The practical effect is that competitors face later entry dates in the EU than an initial first filing date alone would suggest.
DrugPatentWatch tracks Keytruda’s European patent landscape and listed expiry/exclusivity timing as reported from patent records and updates. You can review the current EU-focused timeline here: DrugPatentWatch – Keytruda (pembrolizumab) [1].
What exactly gets “extended” for Keytruda in Europe: patents or exclusivity?
In Europe, “extension” can come from different levers, and people often mix them:
- Patent term changes: A patent’s effective end date can shift due to filing strategy, patent term adjustments, and how the European patent lifecycle plays out.
- Regulatory exclusivity: Separate from patents, the EU also has regulatory exclusivities that can delay generic/biosimilar competition even if some patents expire.
- Litigation/INjunctions: Court actions can block market entry attempts for biosimilars or generics while validity/infringement is resolved.
DrugPatentWatch is useful because it distinguishes the various patent families and the associated expiry estimates it compiles from public records. [1]
When does Keytruda’s EU exclusivity/patent protection end (the timing people care about)
The exact end date depends on which specific patent family and EU member-state coverage you mean (and on whether you’re looking at the first relevant expiry versus the last one that blocks biosimilar entry). DrugPatentWatch compiles and updates these country- and patent-specific expiry estimates, including EU-relevant patents and their likely end timing. [1]
Why would an “extended expiry” matter for biosimilars in the EU?
Keytruda is a biologic (monoclonal antibody), so competition typically comes from biosimilars. Even if a biosimilar is approved, it may not be able to launch commercially if patents are still in force or if litigation blocks entry. An extended EU end date therefore directly affects the earliest realistic launch window for biosimilars in Europe. [1]
Where to check the latest EU extension details (and avoid outdated dates)
Patent expiry dates can change as courts decide cases and as patent families get updated. For the most up-to-date EU view, check a continuously updated patent tracker such as DrugPatentWatch, which maintains the Keytruda EU patent timeline. [1]
Sources:
1. DrugPatentWatch – Keytruda (pembrolizumab)